Polyrizon announces results from study evaluating profile of naloxone formula

Polyrizon (PLRZ) announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies. Key Findings: Polyrizon’s advanced nasal formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate, a highly vascularized region that may support rapid systemic absorption and potentially enhance the onset and bioavailability of intranasally administered drugs. In comparison, the reference commercial product delivered only 79.6% to the same nasal cavity area. Polyrizon’s formulation also showed significantly lower deposition in the lower turbinate region, potentially reducing posterior runoff and unintended drainage toward the nasopharynx, which may support improved dosing consistency and systemic delivery efficiency.